Back Back
RCB2537 : TFK-1  update : 2018/08/02
CommentHuman cell line derived from extrahepatic bile duct carcinoma. TKG0367 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsBasically, there is no restriction regarding academic use.
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC( regarding any kind of for-profit use.
Basic information Depositor Fukuda, Hiroshi
Originator Saijyo, S.
Year of deposit 2007
Original cell TKG0367
Animal human < Mammals
Genus Homo
Species sapiens
Gender Male
Age at sampling 63 years
Tissue common bile duct
Case history papillary adenocarcinoma,
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0367)
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 6 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR (human) OK
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
deposit info
lot info
Reference information Reference 3
User's Publication 21

To topTop
5034  Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.  Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, Matsuno S.  Tohoku J Exp Med  1995  177(1):61-71  PubMed ID: 8693487
5035  SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis.  Sakurai N, Kudo T, Suzuki M, Tsumoto K, Takemura S, Kodama H, Ebara S, Teramae A, Katayose Y, Shinoda M, Kurokawa T, Hinoda Y, Imai K, Matsuno S, Kumagai I.  Biochem Biophys Res Commun  1999  256(1):223-30  PubMed ID: 10066451
5036  Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma.  Kodama H, Suzuki M, Katayose Y, Shinoda M, Sakurai N, Takemura S, Yoshida H, Saeki H, Ichiyama M, Tsumoto K, Asano R, Kumagai I, Imai K, Hinoda Y, Matsuno S, Kudo T.  Cancer Immunol Immunother  2001  50(10):539-48  PubMed ID: 11776376

To topTop
User's Publication
7201  Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies.  Fujimori T, Kato K, Fujihara S, Iwama H, Yamashita T, Kobayashi K, Kamada H, Morishita A, Kobara H, Mori H, Okano K, Suzuki Y, Masaki T.  Oncol. Rep.  2015  34:2987-96  PubMed ID: 26398221
7429  DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.  Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A.  PLoS ONE  2015  10:e0120545  PubMed ID: 25799509
9515  A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.  Sakamoto T, Kobayashi S, Yamada D, Nagano H, Tomokuni A, Tomimaru Y, Noda T, Gotoh K, Asaoka T, Wada H, Kawamoto K, Marubashi S, Eguchi H, Doki Y, Mori M.  PLoS ONE  2016  11:e0145985  PubMed ID: 26726879
9668  Src as a Therapeutic Target in Biliary Tract Cancer.  Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.  Mol. Cancer Ther.  2016  15:1515-24  PubMed ID: 27196758
9700  Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.  Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, Kalthoff H, Egberts JH, Braun F.  BMC Cancer  2016  16:322  PubMed ID: 27206490
10312  Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.  Račkauskas R, Zhou D, Ūselis S, Strupas K, Herr I, Schemmer P.  Oncol. Rep.  2017  37:3660-3666  PubMed ID: 28498473
10816  Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition.  Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Aso K, Makino Y, Fujii S, Ota T, Haneda M.  Oncotarget  2018  9:16400-16417  PubMed ID: 29662654
10834  Combined Gemcitabine and Metronidazole Is a Promising Therapeutic Strategy for Cancer Stem-like Cholangiocarcinoma.  Kawamoto M, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Kawabe K, Onishi H, Nakamura M, Morisaki T.  Anticancer Res.  2018  38:2739-2748  PubMed ID: 29715094
10838  Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.  Huang CK, Iwagami Y, Zou J, Casulli S, Lu S, Nagaoka K, Ji C, Ogawa K, Cao KY, Gao JS, Carlson RI, Wands JR.  Cancer Lett.  2018  429:1-10  PubMed ID: 29733964
11090  MicroRNA-31 reflects IL-6 expression in cancer tissue and is related with poor prognosis in bile duct cancer.  Ishigami K, Nosho K, Koide H, Kanno S, Mitsuhashi K, Igarashi H, Shitani M, Motoya M, Kimura Y, Hasegawa T, Kaneto H, Takemasa I, Suzuki H, Nakase H.  Carcinogenesis  2018  39(9):1127-1134  PubMed ID: 29860474
11166  Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.  Okumura Y, Noda T, Eguchi H, Sakamoto T, Iwagami Y, Yamada D, Asaoka T, Wada H, Kawamoto K, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M.  Ann. Surg. Oncol.  2018  25(12):3728-3737  PubMed ID: 30105440
11476  Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.  Wei K, Li M, Zöller M, Wang M, Mehrabi A, Hoffmann K.  Cell Death Dis  2019    PubMed ID: 30850583
4244  Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.  Nam AR, Jin MH, Park JE, Bang JH, Oh DY, Bang YJ.  Cancer Res Treat  2018    PubMed ID: 30514066
4245  Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.  Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ.  Cancer Res Treat  2018    PubMed ID: 30282449
4339  FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.  Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Fujishima F, Unno M.  Cancer Sci.  2018    PubMed ID: 30302867
4360  Mitochondrial pyruvate carrier modulates the epithelial-mesenchymal transition in cholangiocarcinoma.  Ohashi T, Eguchi H, Kawamoto K, Konno M, Asai A, Colvin H, Ueda Y, Takaoka H, Iwagami Y, Yamada D, Asaoka T, Noda T, Wada H, Gotoh K, Kobayashi S, Koseki J, Satoh T, Ogawa K, Doki Y, Mori M, Ishii H.  Oncol. Rep.  2018  39(3):1276-1282  PubMed ID: 29286150
4891  Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR.  Peraldo Neia C, Cavalloni G, Balsamo A, Venesio T, Napoli F, Sassi F, Martin V, Frattini M, Aglietta M, Leone F.  Genes Chromosomes Cancer  2014  53(12):1033-40  PubMed ID: 25231053
3722  Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.  Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y.  Cancer Sci  2012  103(2):252-61  PubMed ID: 22044563
3735  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.  Saha SK et al  Cancer Discov  2016  6(7):727-39  PubMed ID: 27231123
5767  Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation.  Ito M, Sun S, Fukuhara T, Suzuki R, Tamai M, Yamauchi T, Nakashima K, Tagawa Y, Okazaki S, Matsuura Y, Wakita T, Suzuki T.  Oncotarget  2017  8(33):53899-53915  PubMed ID: 28903311
11552  UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals.  Yu J, Shi L, Shen X, Zhao Y.  Biochem. Pharmacol.  2019    PubMed ID: 31085159

Back Back Return Top Page